Andrew Hantel and Lauren Merz
Nov 20, 2025, 14:05
Andrew Hantel and Lauren Merz Had an Important Conversation About Appropriate Care
American Society of Hematology shared a post on LinkedIn:
“The Duffy-null phenotype is common among individuals of African, Middle Eastern, and North African ancestry, yet often misunderstood — leading to unnecessary procedures, inappropriate dose modifications, and exclusion from potentially life-saving therapies.
Join experts Drs. Andrew Hantel and Lauren Merz for an important conversation about appropriate care. Learn how Duffy-null affects absolute neutrophil counts (ANCs), clinical trial eligibility, and treatment decisions, including:
- How standard ANC cutoffs can disadvantage patients
- Implications for chemotherapy, immunosuppressive drugs, and clozapine
- The intersection of Duffy-null with recent updates to CTC AE grading
Listen now here.”
Read more here.
Stay informed with Hemostasis Today.
-
Dec 16, 2025, 16:14Nicolas Gendron on Sustainability in Anticoagulation and DOACs
-
Dec 16, 2025, 15:39Reza Shojaei: Every Expired Unit of Blood Tells a Story
-
Dec 16, 2025, 14:03Francesco Lo Monaco on Rethinking Blood Pressure: The Major Problem with How We Understand It
-
Dec 16, 2025, 14:03Marilena Vrana Urges EU Policymakers to “Keep Patients at the Centre” of Critical Medicines Act
-
Dec 16, 2025, 14:02Even Distribution of Protective Hemoglobin Prevents Sickle Cell Symptoms
-
Dec 16, 2025, 13:58AHA Awards Shubham Misra Postdoc Grant for LVO Stroke Biomarker Research
-
Dec 16, 2025, 13:00ScholarGPS Ranks Emmanuel J. Favaloro No. 1 in the World for Hemostasis
-
Dec 16, 2025, 11:30Kingsley Wheaton: Sweden is on the Brink of Becoming the World’s 1st Smoke-Free Country
-
Dec 16, 2025, 11:03Matías J Alet on CABOS Project with The Support of WSO